Psilocybin shields sensory nerves from chemotherapy injury in mice

Giving the psychedelic compound ahead of cancer treatment stopped peripheral nerve damage in animal tests by preserving the transport of cellular power plants.

When cancer enters remission, the relief of surviving a life-threatening illness often collides with a lasting neurological burden. The nerve endings that extend into human fingertips and toes can wither during chemotherapy, leaving hands and feet numb, painfully hypersensitive to touch, or stinging with cold.¹²³ Clinicians call this peripheral neuropathy, a debilitating condition that can persist for years after oncological treatment ends.³²

For people receiving standard chemotherapy regimens, the problem is both widespread and difficult to prevent. Platinum-based drugs, which treat common malignancies of the lungs and ovaries, along with taxane therapies, frequently injure the longest nerve fibers in the body.¹² Once those peripheral axons sustain structural damage, existing medical therapies cannot repair them, and doctors are frequently forced to lower chemotherapy doses or halt curative treatment cycles entirely.²¹

A study published in the journal Science reveals an unexpected biological defence against that nerve injury.¹³ Researchers found that administering psilocybin, the psychoactive molecule found in magic mushrooms, before cycles of chemotherapy protected peripheral nerve fibers from breakdown in preclinical models.¹³ The chemical intervention prevented pain hypersensitivity and preserved normal touch sensation without dampening the cancer-fighting potency of the chemotherapy itself.¹³

How does chemotherapy injure peripheral nerves?

Chemotherapy drugs cause peripheral neuropathy by cutting off the energy supply needed to keep distant nerve terminals alive.¹² Sensory neurons are among the longest cells in the mammalian body, extending from cell bodies near the spinal cord all the way into the outer layers of the skin.¹² To survive and communicate sensations of heat, cold, and pressure, these terminal nerve endings require a continuous supply of adenosine triphosphate, the basic chemical fuel produced by microscopic organelles called mitochondria.²¹

Mitochondria do not originate at the skin surface.¹² Instead, they must be continuously transported along internal structural tracks from the neuron's cell body down to its distant tips.¹² Chemotherapeutic compounds such as cisplatin disrupt this transport system, stalling the movement of mitochondria along the axon.²³ Depleted of energy, the fragile distal endings starve, wither, and trigger aberrant electrical signals that register as persistent numbness and burning pain.¹²

According to the paper in Science, introducing psilocybin before chemotherapy keeps those cellular engines moving along the nerve fibers.¹³ The compound binds directly to 5-HT2A serotonin receptors located on peripheral sensory neurons.³² That chemical binding initiates an intracellular signaling cascade, involving the TrkB-Akt-PAK5-MAP2-KIF5B molecular pathway, which mobilizes motor proteins and frees stationary mitochondria so they can continue journeying to the nerve tips.² By sustaining the delivery of cellular power, the nerve endings remain intact and functioning throughout the toxic chemotherapy exposure.³²

What did the experiments show?

Preclinical tests demonstrated that preventive dosing stopped the emergence of neuropathic pain across multiple chemotherapy models.³² In the initial experiments described in the paper, researchers led by co-senior authors Moran Amit, an assistant professor of Head and Neck Surgery, and Patrick Dougherty, a professor of Pain Medicine at The University of Texas MD Anderson Cancer Center, administered two doses of psilocybin to mice prior to chemotherapy exposure.³¹² Animals that received psilocybin showed complete protection against cisplatin-induced mechanical hypersensitivity, whereas untreated control mice developed painful tactile sensitivity and diminished cutaneous nerve density.²¹

The protection also held up during long-term chemotherapy regimens that mirror clinical treatment. In mice exposed to six monthly rounds of cisplatin across eight months of follow-up, cycle-matched psilocybin pretreatments preserved tactile acuity, averted hypersensitivity to cold, and prevented the pruning of epidermal sensory nerve fibers.²¹ Similar neuroprotective effects occurred in models testing taxane chemotherapies, including paclitaxel and docetaxel.³²

The team also confirmed that the compound's protective activity did not shield cancer cells from the chemotherapy. In syngeneic oral cancer mouse models, psilocybin preserved nerve fibers without altering tumor growth, systemic cytokine profiles, or chemotherapy's ability to shrink tumors.²¹ Pharmacological tests proved the mechanism was dependent on the serotonin receptor: when researchers blocked 5-HT2A receptors with the antagonist volinanserin, psilocybin lost its ability to prevent mechanical hypersensitivity.²

Crucially, the cellular protection did not require a psychedelic trip. When the authors tested tabernanthalog, a non-hallucinogenic compound that stimulates the same 5-HT2A receptor, treated mice achieved comparable protection against sensory nerve loss and mechanical hypersensitivity.¹² That finding suggests that the molecular machinery preserving nerve endings operates independently of the perceptual alterations produced in the brain.¹²

How did the researchers verify the mechanism?

Researchers verified the neuroprotective process through cellular tracking, electrophysiology, and experiments on surgical human tissue. The investigation, which included primary author M. Heles and colleagues, evaluated sensorimotor performance in mice using von Frey filaments to test touch sensitivity, acetone evaporation to test cold sensitivity, and behavioral tape-removal and nesting assays.²¹ At the same time, patch-clamp recordings from dorsal root ganglion neurons and microelectrode arrays in the medial prefrontal cortex demonstrated that psilocybin restored healthy cortical network dynamics and electroencephalography power bands disrupted by chemotherapy.²

To see whether the mechanism functioned in people, the researchers examined human stem cell-derived sensory neurons, organ donor tissue, and peripheral nerve samples harvested from 29 surgical patients.² Live-cell imaging showed that cisplatin halted mitochondrial motility in human peripheral nerves, reducing both movement frequency and transport velocity.² Exposing those human nerve tissues to psilocybin counteracted the chemical paralysis, preserving mitochondrial trafficking and maintaining local energy distribution along the axons.²

Independent researchers noted the novelty of targeting mitochondrial movement through a psychedelic receptor. Joe Cichon, a neuroanaesthesiologist at the University of Pennsylvania in Philadelphia, called the preventive protocol a clever treatment approach, observing that finding psilocybin regulating mitochondrial transport along sensory neurons was unexpected.¹

What remains unproven about this approach?

These findings come entirely from laboratory animals, cell cultures, and excised tissue samples, meaning they cannot tell clinicians whether psilocybin will safely prevent neuropathy in human cancer patients.²³ Laboratory mice kept in controlled environments experience chemotherapy differently than human patients undergoing complex, multi-drug oncological care. In addition, living human nerves inside a clinical patient may respond to long-term receptor stimulation with biological tolerances or side effects that cannot appear in short-term ex vivo tissue baths.

The experimental setup tested prophylactic administration, meaning the drug was introduced before nerve injury happened. The data do not show whether psilocybin can repair nerve fibers or reverse burning pain once chronic peripheral neuropathy has already taken hold.³¹ Furthermore, although animal tumor models showed no drop in chemotherapy efficacy, human clinical trials must independently verify that activating 5-HT2A receptors does not inadvertently protect diverse human tumor types against cytotoxic treatment.²

What happens next?

The immediate next step is evaluating whether the biological mechanism holds true in human clinical trials. Investigators at MD Anderson are launching an upcoming Phase 2 clinical trial named NeuroGuard, registered under identifier NCT07227909, to evaluate psilocybin administration during chemotherapy in patients diagnosed with multiple cancer types.³ The trial will measure whether the preventive effects observed in laboratory rodents translate into measurable reductions in human nerve pain, numbness, and treatment interruptions.³

At the same time, the demonstration that non-hallucinogenic molecules like tabernanthalog provide equivalent nerve protection points toward a wider pharmaceutical horizon.²¹ If synthetic molecules can engage peripheral serotonin receptors without generating altered states of consciousness, patients might one day receive neuroprotective infusions alongside chemotherapy without requiring specialised psychiatric supervision.

This piece was prepared from the paper in Science and public records; the authors have not been interviewed.

What this rests on

39 sentences trace to 3 sources.

All 3Documents 2Records 0Reporting 1People 0

1. 1 U us.list-manage.com Document · us.list-manage.com Psilocybin blocks chemo side-effect See the source
2. 2 N news-medical.net Third-party reporting · news-medical.net Psilocybin protects sensory nerves from chemotherapy damage in preclinical study See the source
3. 3 UM UT MD Anderson Press release · mdanderson.org · 3 Sep 2026 Psilocybin prevents chemotherapy-related nerve injury and associated symptoms in preclinical models See the source